Duppla Drives Financial Inclusion in Colombia With Begini's Behavioural Data Insights
BOGOTÁ, Colombia--(BUSINESS WIRE)-- Duppla, a Colombian PropTech startup, has successfully deployed Begini's behavioural data solution to accelerate its rent-to-own model, supporting its mission to unlock homeownership for underserved families.
'This is the kind of partnership that validates both our vision and our execution,' said James Hume, CEO, Begini. 'We're not just improving credit scoring; we're reshaping how financial institutions think about inclusion and risk in emerging economies.'
Begini's platform has enabled Duppla to enhance credit assessment processes, expand access to its housing solution, and gain strategic insights to support sustainable portfolio growth.
Facing the challenge of serving credit-invisible consumers typically excluded by traditional financial institutions, Duppla turned to Begini, a behavioural data platform that enables ethical and predictive decision-making for thin-file customers. With Begini's solution, Duppla achieved same-day integration, launching psychometric credit evaluations with minimal technical effort.
Since launch, Duppla has seen remarkable adoption: 93% of applicants have completed the assessment process, validating the user-centric design and intuitive interface of Begini's solution. Initially introduced as a complementary input, Begini's psychometric score is now a core component of Duppla's credit policy.
'The psychometric score is critical in our customer acceptance policy,' said Nicolás Ayala, from Duppla. 'Begini enables us to analyse risk in ways traditional systems cannot, which helps us extend access while maintaining portfolio quality.'
Beyond credit scoring, Duppla has embraced the broader potential of character-based insights. Personality traits such as conscientiousness, honesty, and moderation, delivered as part of Begini's assessments, are now analysed to improve customer lifecycle value, and long-term engagement.
This partnership has also reshaped internal alignment. The sales team, initially uncertain about user receptiveness, now promotes the psychometric assessment as a gateway to benefits and tailored offers. Internally, commercial staff have also seen value: by leveraging Begini's insights, they can approve more applicants responsibly, aligning incentives across customer acquisition and portfolio growth.
Begini's solution has become a strategic asset in attracting and reassuring investors. By strengthening risk controls and demonstrating scientific, data-driven underwriting, Duppla has enhanced transparency and trust for those financing their housing assets.
'One of the top questions we get from stakeholders is how we manage risk given our customer segment,' said Ayala. 'Begini has allowed us to present a robust, innovative process that sets us apart and builds real confidence in our growth model.'
'This is the kind of partnership that validates both our vision and our execution,' said James Hume, CEO, Begini. 'We're not just improving credit scoring; we're reshaping how financial institutions think about inclusion and risk in emerging economies.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
35 minutes ago
- Business Wire
Pharmaceuticals and Biotechnology Option and Evaluation Agreements Analysis Report 2025 with Directory of Deals Signed Since 2019 - Upfront, Royalty, Milestone Financials
DUBLIN--(BUSINESS WIRE)--The "Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2019-2025" has been added to offering. This report contains a comprehensive listing of option and evaluation deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners. Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter option and evaluation deals. Fully revised and updated, the report provides details of option and evaluation deals from 2019 to 2025. The report provides access to option and evaluation deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not. The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities. Chapter 1 introduces the report, followed by Chapter 2 which offers an overview and analysis of the trends in option and evaluation deals, alongside discussing the merits of such deals. Chapter 3 details the structure of option and evaluation deals, while Chapter 4 reviews the leading deals since 2019, ordered by headline value. Chapter 5 lists the top 25 active dealmakers with available links to full records and contracts, and Chapter 6 provides an organized review of deals by company, therapy, technology, and industry type, offering insights into agreed terms. Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits: Understand deal trends since 2019 Browse option and evaluation deals Benchmark analysis - identify market value of transactions Financials terms Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in option and evaluation dealmaking 2.1. Introduction 2.2. Definition of option and evaluation deal 2.3. Trends in option and evaluation deals since 2019 2.3.1. Option and evaluation dealmaking by year, 2019-2025 2.3.2. Option and evaluation dealmaking by phase of development, 2019-2025 2.3.3. Option and evaluation dealmaking by industry sector, 2019-2025 2.3.4. Option and evaluation dealmaking by therapy area, 2019-2025 2.3.5. Option and evaluation dealmaking by technology type, 2019-2025 2.3.6. Option and evaluation dealmaking by most active company, 2019-2025 2.4. Reasons for entering into option and evaluation partnering deals 2.5. The future of option and evaluation deals Chapter 3 - Overview of option and evaluation deal structure 3.1. Introduction 3.2. Option and evaluation agreement structure Chapter 4 - Leading option and evaluation deals 4.1. Introduction 4.2. Top option and evaluation deals by value Chapter 5 - Top 25 most active option and evaluation dealmakers 5.1. Introduction 5.2. Top 25 most active option and evaluation dealmakers Chapter 6 - option and evaluation deals including contracts directory 6.1. Introduction 6.2. Option and evaluation deals with contracts 2019-2025 Deal directory Deal directory - option and evaluation dealmaking by companies A-Z Deal directory - option and evaluation dealmaking by therapy area Deal directory - option and evaluation dealmaking by technology type For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Yahoo
an hour ago
- Yahoo
Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in May
NEW YORK, June 24, 2025--(BUSINESS WIRE)--Lazard Global Total Return and Income Fund, Inc. (the "Fund") (NYSE:LGI) is confirming today, pursuant to its Managed Distribution Policy, as previously authorized by its Board of Directors, a monthly distribution of $0.14646 per share on the Fund's outstanding common stock. The distribution is payable on July 22, 2025 to shareholders of record on July 10, 2025. The ex-dividend date is July 10, 2025. The Fund will pay a previously declared distribution today, June 24, 2025. The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid, including today's distribution, from the following sources: net investment income, net realized capital gains (short-term and long-term), and return of capital. All amounts are expressed per share of common stock and are based on accounting principles generally accepted in the US, which may differ from federal income tax regulations. Current Distribution % of the CurrentDistribution Total CumulativeDistributions for theFiscal Year to Date % of the Total CumulativeDistributions for the FiscalYear to Date Net Income $0.06371 43% $0.06371 7% Net Realized Short-Term Capital Gains $0.00375 3% $0.02250 3% Net Realized Long-Term Capital Gains $0.00025 0% $0.25018 28% Return of Capital $0.07875 54% $0.54237 62% Total $0.14646 100% $0.87876 100% Average annual total return (in relation to NAV) for the 5-year period ending on May 31, 2025 10.39% Annualized current distribution rate expressed as a percentage of NAV as of May 31, 2025 10.09% Cumulative total return (in relation to NAV) for the fiscal year through May 31, 2025 3.27% Cumulative fiscal year distributions as a percentage of NAV as of May 31, 2025 4.21% You should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's Managed Distribution Policy. The Fund estimates that it has distributed more than its net investment income and net realized capital gains; therefore, a portion of your distribution may be return of capital. A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with "yield" or "income". The amounts and sources of distributions reported above are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund provides financial intermediary firms the information necessary to produce the Form 1099-DIV, and then the relevant financial intermediary firm will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes. If you have any questions, or need additional information, please call us at 1-800-823-6300. Portfolio data as of May 31, 2025, including performance, asset allocation, top 10 holdings, sector weightings, regional exposure, and other Fund characteristics have been posted on Lazard Asset Management's ("LAM") website, The Fund's investment objective is total return, consisting of capital appreciation and current income. The Fund's net assets are invested in a portfolio of approximately 60 to 80 US and non-US equity securities, including American Depository Receipts, generally of companies with market capitalizations greater than $2 billion, and may include investments in emerging markets. The Fund also invests in emerging market currencies (primarily by entry into forward currency contracts), or instruments whose value is derived from the performance of an underlying emerging market currency, and also may invest in debt obligations, including government, government agency and corporate obligations and structured notes denominated in emerging market currencies. An indirect subsidiary of Lazard, Inc. (NYSE: LAZ), LAM, the Fund's investment manager, offers a range of equity, fixed-income, and alternative investment products worldwide. As of May 31, 2025, LAM and affiliated asset management companies in the Lazard Group managed $235.3 billion worth of client assets. For more information about LAM, please go to Follow LAM at @LazardAsset. View source version on Contacts Media contact:Aziz Nayani, +1 212 632 Investor contact:Ben Wulfsohn, +1 800 823 Sign in to access your portfolio
Business Wire
an hour ago
- Business Wire
Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in May
NEW YORK--(BUSINESS WIRE)--Lazard Global Total Return and Income Fund, Inc. (the "Fund") (NYSE:LGI) is confirming today, pursuant to its Managed Distribution Policy, as previously authorized by its Board of Directors, a monthly distribution of $0.14646 per share on the Fund's outstanding common stock. The distribution is payable on July 22, 2025 to shareholders of record on July 10, 2025. The ex-dividend date is July 10, 2025. The Fund will pay a previously declared distribution today, June 24, 2025. The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid, including today's distribution, from the following sources: net investment income, net realized capital gains (short-term and long-term), and return of capital. All amounts are expressed per share of common stock and are based on accounting principles generally accepted in the US, which may differ from federal income tax regulations. Average annual total return (in relation to NAV) for the 5-year period ending on May 31, 2025 10.39% Annualized current distribution rate expressed as a percentage of NAV as of May 31, 2025 10.09% Cumulative total return (in relation to NAV) for the fiscal year through May 31, 2025 3.27% Cumulative fiscal year distributions as a percentage of NAV as of May 31, 2025 4.21% Expand You should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's Managed Distribution Policy. The Fund estimates that it has distributed more than its net investment income and net realized capital gains; therefore, a portion of your distribution may be return of capital. A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with "yield" or "income". The amounts and sources of distributions reported above are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund provides financial intermediary firms the information necessary to produce the Form 1099-DIV, and then the relevant financial intermediary firm will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes. If you have any questions, or need additional information, please call us at 1-800-823-6300. Portfolio data as of May 31, 2025, including performance, asset allocation, top 10 holdings, sector weightings, regional exposure, and other Fund characteristics have been posted on Lazard Asset Management's ("LAM") website, The Fund's investment objective is total return, consisting of capital appreciation and current income. The Fund's net assets are invested in a portfolio of approximately 60 to 80 US and non-US equity securities, including American Depository Receipts, generally of companies with market capitalizations greater than $2 billion, and may include investments in emerging markets. The Fund also invests in emerging market currencies (primarily by entry into forward currency contracts), or instruments whose value is derived from the performance of an underlying emerging market currency, and also may invest in debt obligations, including government, government agency and corporate obligations and structured notes denominated in emerging market currencies. An indirect subsidiary of Lazard, Inc. (NYSE: LAZ), LAM, the Fund's investment manager, offers a range of equity, fixed-income, and alternative investment products worldwide. As of May 31, 2025, LAM and affiliated asset management companies in the Lazard Group managed $235.3 billion worth of client assets. For more information about LAM, please go to Follow LAM at @LazardAsset.
